Enanta pharmaceuticals, inc. (ENTA)
CashFlow / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11
Cash flows from operating activities
Net income

46,383

71,956

17,710

21,666

78,992

34,438

9,627

21,399

23,310

Adjustments to reconcile net income to net cash provided by operating activities:
Gain on embedded derivative

-

-

-

-

-

-

-

0

670

Stock-based compensation expense

19,226

15,845

13,071

9,354

5,838

2,682

1,063

424

225

Depreciation and amortization expense

3,258

2,518

2,137

1,661

639

352

221

172

499

Deferred income taxes

-3,138

1,858

-1,654

-2,294

11,028

-15,211

-

-

-

Income tax benefit from stock awards

-

-

213

1,747

1,814

110

-

-

-

Gain on disposal of property and equipment

-

-

-

-

-

-

100

63

7

Premium paid on marketable securities

1,491

319

1,229

518

3,042

2,002

1,811

-

-

Accretion of discount on marketable securities

4,336

835

-702

-1,511

-2,244

-2,120

-1,262

-590

-317

Non-cash interest expense

-

-

-

-

-

-

31

-

2,059

Change in fair value of warrant liability and Series 1 nonconvertible preferred stock

-

-59

-159

29

347

-166

381

-8

-686

Other non-cash items

-25

75

-

-34

35

-2

-

-

-

Change in operating assets and liabilities:
Accounts receivable

-15,892

56,591

-2,227

-2,448

13,565

916

-241

788

251

Unbilled receivables

-

-

-

-433

-2,337

1,986

-1,109

1,893

-

Prepaid expenses and other current assets

10,845

918

-5,678

964

6,680

-568

307

235

273

Other assets

-

-

-

-

-

-

-22

-5

26

Accounts payable

1,791

1,317

633

1,451

-543

399

115

763

58

Accrued expenses

5,750

1,843

3,443

1,858

-227

-183

-285

1,726

-1,120

Income taxes payable

-1,388

-7,910

9,511

548

1,199

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-7

17

-432

Other long-term liabilities

291

564

478

397

649

-140

-147

498

-356

Other long-term assets

-

92

-

-

-

-

-

-

-

Sale of marketable securities

-

-

-

-

2,210

8,421

5,453

15,750

16,764

Net cash provided by operating activities

71,418

29,220

52,653

35,809

76,673

20,179

10,653

22,623

24,019

Cash flows from investing activities
Proceeds from sales of property and equipment

-

-

-

-

-

-

-

66

9

Purchase of marketable securities

549,312

293,103

251,371

192,429

196,304

98,405

115,888

47,694

33,574

Maturities of marketable securities

-

-

-

-

108,407

91,506

41,825

12,950

-

Proceeds from maturities and sale of marketable securities

468,065

260,682

249,305

153,504

-

-

-

-

-

Purchase of property and equipment

5,417

2,981

2,506

4,738

2,336

1,028

606

252

445

Other investing activities

-

-

-

-

163

-3

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-1,140

436

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

2,000

Repayment of convertible notes

-

-

-

-

-

-

-

-

2,000

Proceeds from initial public offering, net of underwriting discounts and commissions

-

-

-

-

-

-

59,892

-

-

Net cash used in investing activities

-86,664

-35,402

-4,572

-43,663

-88,186

497

-69,216

-18,040

-17,682

Cash flows from financing activities
Proceeds from exercise of stock options

6,848

6,244

1,079

1,026

726

1,054

559

141

34

Payments of initial public offering costs

-

-

-

-

-

-

3,540

1,050

-

Income tax benefit from exercise of stock options

-

-

213

1,747

1,814

110

-

-

-

Payments for settlement of share-based awards

4,188

1,756

202

-

-

-

-

-

-

Payments of capital lease obligations

86

79

73

68

-

-

-

-

-

Net cash provided by financing activities

2,574

4,409

1,017

2,705

2,540

1,164

56,911

-909

34

Net increase (decrease) in cash, cash equivalents and restricted cash

-12,672

-1,773

49,098

-5,149

-8,973

21,840

-1,652

3,674

6,371

Supplemental disclosure of cash flow information:
Cash paid for income taxes

12,672

26,088

1,588

12,616

40,072

148

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

0

1,056

Supplemental disclosure of non-cash investing information:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

2,526

5,367

5,454

Initial public offering costs included in accounts payable or accrued expenses

-

-

-

-

-

-

-

1,079

0

Conversion of preferred stock into common stock

-

-

-

-

-

-

161,808

0

0

Exercise of Series 1 warrants into Series 1 nonconvertible preferred stock

-

-

-

-

-

206

-

-

-

Purchases of fixed assets included in accounts payable and accrued expenses

320

111

318

637

1,562

-

-

-

-

Fixed assets financed by landlord

-

-

-

-

239

-

-

-

-

Fixed assets purchased through capital lease

-

-

-

-

598

-

-

-

-